ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 219,14
0,38%
Dow Jones
39 512,84
0,32%
DAX
18 772,85
0,50%
Brent Oil
82,585
0,00%
Bitcoin
60 898,05
0,17%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Royaume-Uni
  5. LSE
  6. Hikma Pharmaceuticals Plc (HIK)

  7. Hikma Pharmaceuticals Plc (HIK) Actualités

HIK

Hikma Pharmaceuticals (HIK)

Hikma Pharmaceuticals Plc
De:
Trier par:
 Showing the most relevant articles for your search:LSE:HIK
DateHeureSourceTitreSymboleSociété
09/05/202410h49RNS Regulatory NewsHikma Pharmaceuticals Plc Director/PDMR ShareholdingLSE:HIKHikma Pharmaceuticals Plc
25/04/202415h28RNS Regulatory NewsHikma Pharmaceuticals Plc Result of AGMLSE:HIKHikma Pharmaceuticals Plc
25/04/202411h15Alliance NewsAlliance NewsHikma Pharmaceuticals backs outlook after making strong start to 2024LSE:HIKHikma Pharmaceuticals Plc
25/04/202408h00RNS Regulatory NewsHikma Pharmaceuticals Plc Trading StatementLSE:HIKHikma Pharmaceuticals Plc
15/04/202417h43RNS Regulatory NewsHikma Pharmaceuticals Plc Hikma appoints new President of Generics businessLSE:HIKHikma Pharmaceuticals Plc
02/04/202410h50RNS Regulatory NewsHikma Pharmaceuticals Plc Block listing Interim ReviewLSE:HIKHikma Pharmaceuticals Plc
22/03/202410h21RNS Regulatory NewsHikma Pharmaceuticals Plc Annual Financial Report and Notice of AGMLSE:HIKHikma Pharmaceuticals Plc
01/03/202411h17RNS Regulatory NewsHikma Pharmaceuticals Plc Total Voting RightsLSE:HIKHikma Pharmaceuticals Plc
22/02/202410h42Alliance NewsAlliance NewsTOP NEWS: Hikma boosts dividend after year of "significant progress"LSE:HIKHikma Pharmaceuticals Plc
22/02/202408h09Alliance NewsAlliance News*Hikma Pharmaceuticals says core operating profit to be in range of USD660m to USD700mLSE:HIKHikma Pharmaceuticals Plc
22/02/202408h08Alliance NewsAlliance News*Hikma Pharmaceuticals expect revenue to grow in the range of 4% to 6%LSE:HIKHikma Pharmaceuticals Plc
22/02/202408h08Alliance NewsAlliance News*Hikma Pharmaceuticals confident that strategy will continue to deliver growth in 2024LSE:HIKHikma Pharmaceuticals Plc
22/02/202408h07Alliance NewsAlliance News*Hikma Pharmaceuticals declares FY dividend of 73 US cents per share vs 56 cents YoYLSE:HIKHikma Pharmaceuticals Plc
22/02/202408h06Alliance NewsAlliance News*Hikma Pharmaceuticals 2023 pretax profit USD520m vs USD233m YoYLSE:HIKHikma Pharmaceuticals Plc
22/02/202408h06Alliance NewsAlliance News*REPEAT: Hikma Pharmaceuticals 2023 revenue USD2.88b vs USD2.52b YoYLSE:HIKHikma Pharmaceuticals Plc
22/02/202408h05Alliance NewsAlliance News*Hikma Pharmaceuticals 2023 USD2.88b vs USD2.52b YoYLSE:HIKHikma Pharmaceuticals Plc
22/02/202408h00RNS Regulatory NewsHikma Pharmaceuticals Plc Final ResultsLSE:HIKHikma Pharmaceuticals Plc
21/02/202419h20UK RegulatoryHikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facilityLSE:HIKHikma Pharmaceuticals Plc
20/02/202418h24Alliance NewsAlliance NewsEARNINGS PREVIEW: Eyes on Hikma's outlook ahead of full-year resultsLSE:HIKHikma Pharmaceuticals Plc
05/02/202413h00UK RegulatoryHikma announces US launch of COMBOGESIC® IVLSE:HIKHikma Pharmaceuticals Plc
05/02/202409h46RNS Regulatory NewsHikma Pharmaceuticals Plc Notice of ResultsLSE:HIKHikma Pharmaceuticals Plc
01/02/202421h00Alliance NewsAlliance NewsEARNINGS AND TRADING: Tandem FY sales down 17%; Hikma's opioid dealLSE:HIKHikma Pharmaceuticals Plc
01/02/202419h22RNS Regulatory NewsHikma Pharmaceuticals Plc Agreement in Principle for US Opioid SettlementLSE:HIKHikma Pharmaceuticals Plc
29/12/202308h00UK RegulatoryHikma Pharmaceuticals Plc Company Secretary ChangeLSE:HIKHikma Pharmaceuticals Plc
02/11/202309h53Alliance NewsAlliance NewsTOP NEWS: Hikma Pharmaceuticals upgrades Generics and Branded guidanceLSE:HIKHikma Pharmaceuticals Plc
03/10/202313h00PR Newswire (US)Hikma marks two-year anniversary of KLOXXADO® launch by surpassing 375,000 doses donated in the USLSE:HIKHikma Pharmaceuticals Plc
30/08/202318h55Alliance NewsAlliance NewsTOP NEWS: M&S returns to FTSE 100 after four years, Persimmon exitsLSE:HIKHikma Pharmaceuticals Plc
23/08/202315h07Alliance NewsAlliance NewsIN DEPTH: M&S set for blue-chip return as Hikma-Dechra yo-yo continuesLSE:HIKHikma Pharmaceuticals Plc
22/08/202318h26Alliance NewsAlliance NewsTOP NEWS: M&S set to be FTSE 100 outfit again but Persimmon may fallLSE:HIKHikma Pharmaceuticals Plc
10/08/202314h28PR Newswire (US)Rakuten Medical and Hikma Sign Exclusive Licensing Agreement for Alluminox™ Platform Cancer Treatment in the Middle East and North AfricaLSE:HIKHikma Pharmaceuticals Plc
 Showing the most relevant articles for your search:LSE:HIK

Dernières Valeurs Consultées

NASDAQ
NVDA
NVIDIA
COIN
ETHUSD
Ethereum
EU
LR
Legrand
EU
BN
Danone
NYSE
NKE
Nike
NASDAQ
AAPL
Apple
EU
ACA
Credit Agricole
EU
AF
Air FranceKLM
EU
GLE
Societe Generale
EU
VK
Vallourec
EU
RNO
Renault
NASDAQ
GOOGL
Alphabet
NYSE
JPM
JP Morgan Chase
NASDAQ
MSFT
Microsoft
EU
HO
Thales
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés